Macrogenics MGNX 深 沪
等待开盘 11-06 09:30:00 美东时间
2.23
-0.080
-3.46%
华盛通- 最 高2.3336
- 今 开2.30
- 成交量 34.15万股
- 最 低 2.2099
- 昨 收 2.31
- 总市值 1.42亿
- 52周最高 5.08
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 1.32
- 委 比 53.16%
- 总股本 6370.02万
- 历史最高 41.00
- 量 比 1.58
- 振 幅 5.35%
- 历史最低 0.9897
- 每 手 1
- 风险率 1.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial
Durable responses observed across multiple tumor types during dose escalation MGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patients MGC026 demonstrated manageable safety and tolerability profile with no treatment-re...
10-23 21:24
MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) d...
10-16 04:06
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $32.832 million...
08-14 05:52
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific progra...
08-12 04:22
MacroGenics To Receive $24.5M Milestone From Sanofi Following FDA Approval Of TZIELD Expansion In Type 1 Diabetes
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Adminis...
06-23 04:44
Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 9.38 percent. This is a 10.77 percent increase over losses of $(0.65) per share from the
05-14 04:56
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 79.4% to $12....
05-13 01:06
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.
05-12 18:05
美股夜盘 | 安博教育涨65.40%，Xos, Inc.涨30.69%
微宏控股涨-37.13%；沃氪医疗涨-36.22%；Power Solutions International, Inc.涨-35.77%
05-12 08:05
